APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

T-Cell & NK-Cell Engaging Bispecific Antibodies

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174039380329 December 2025188 pages

Choose your research edition.

Industry ResearchT-Cell & NK-Cell Engaging Bispecific Antibodies Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal T-Cell & NK-Cell Engaging Bispecific Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal T-Cell & NK-Cell Engaging Bispecific Antibodies Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal T-Cell & NK-Cell Engaging Bispecific Antibodies Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global T-Cell & NK-Cell Engaging Bispecific Antibodies market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for T-Cell & NK-Cell Engaging Bispecific Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for T-Cell & NK-Cell Engaging Bispecific Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for T-Cell & NK-Cell Engaging Bispecific Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for T-Cell & NK-Cell Engaging Bispecific Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of T-Cell & NK-Cell Engaging Bispecific Antibodies include Immunocore, MacroGenics, Regeneron, AbbVie, Amgen, Pfizer, Roche and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global T-Cell & NK-Cell Engaging Bispecific Antibodies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of T-Cell & NK-Cell Engaging Bispecific Antibodies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents T-Cell & NK-Cell Engaging Bispecific Antibodies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the T-Cell & NK-Cell Engaging Bispecific Antibodies market size, projected growth trends, production technologies, key applications, and end-use industries.

T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Company

Immunocore

MacroGenics

Regeneron

AbbVie

Amgen

Pfizer

Roche

Johnson & Johnson

T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Type

T-Cell Engagers

NK-Cell Engagers

T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Application

Hematological Cancers

Solid Tumors

T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T-Cell & NK-Cell Engaging Bispecific Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of T-Cell & NK-Cell Engaging Bispecific Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T-Cell & NK-Cell Engaging Bispecific Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the T-Cell & NK-Cell Engaging Bispecific Antibodies market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of T-Cell & NK-Cell Engaging Bispecific Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of T-Cell & NK-Cell Engaging Bispecific Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of T-Cell & NK-Cell Engaging Bispecific Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Trends Table 2. T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Drivers Table 3. T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Opportunities and Challenges Table 4. T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Restraints Table 5. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Manufacturers (2021-2026) Table 7. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Manufacturers Table 9. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturers, Product Type & Application Table 13. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global T-Cell & NK-Cell Engaging Bispecific Antibodies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of T-Cell Engagers Table 17. Major Manufacturers of NK-Cell Engagers Table 18. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2021-2026) & (K Units) Table 20. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2027-2032) & (K Units) Table 21. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2021-2026) Table 22. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2027-2032) Table 23. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type (2021-2026) & (K Units) Table 25. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type (2027-2032) & (K Units) Table 26. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Type (2021-2026) Table 27. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hematological Cancers Table 29. Major Manufacturers of Solid Tumors Table 30. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2021-2026) & (K Units) Table 32. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2027-2032) & (K Units) Table 33. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2021-2026) Table 34. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2027-2032) Table 35. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application (2021-2026) & (K Units) Table 37. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application (2027-2032) & (K Units) Table 38. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Application (2021-2026) Table 39. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Application (2027-2032) Table 40. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2021-2026) & (K Units) Table 42. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Region (2021-2026) Table 43. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Forecasted Market Share by Region (2027-2032) Table 45. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2021-2026) & (K Units) Table 47. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2027-2032) & (K Units) Table 48. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2021-2026) & (K Units) Table 50. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2027-2032) & (K Units) Table 57. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region (2021-2026) & (US$ Million) Table 59. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region (2027-2032) & (US$ Million) Table 60. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Region (2021-2026) Table 61. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Region (2027-2032) Table 62. Immunocore Company Information Table 63. Immunocore Business Overview Table 64. Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 66. Immunocore Recent Development Table 67. MacroGenics Company Information Table 68. MacroGenics Business Overview Table 69. MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 71. MacroGenics Recent Development Table 72. Regeneron Company Information Table 73. Regeneron Business Overview Table 74. Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 76. Regeneron Recent Development Table 77. AbbVie Company Information Table 78. AbbVie Business Overview Table 79. AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 81. AbbVie Recent Development Table 82. Amgen Company Information Table 83. Amgen Business Overview Table 84. Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 86. Amgen Recent Development Table 87. Pfizer Company Information Table 88. Pfizer Business Overview Table 89. Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 91. Pfizer Recent Development Table 92. Roche Company Information Table 93. Roche Business Overview Table 94. Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 96. Roche Recent Development Table 97. Johnson & Johnson Company Information Table 98. Johnson & Johnson Business Overview Table 99. Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio Table 101. Johnson & Johnson Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. T-Cell & NK-Cell Engaging Bispecific Antibodies Distributors List Table 105. T-Cell & NK-Cell Engaging Bispecific Antibodies Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. T-Cell & NK-Cell Engaging Bispecific Antibodies Product Image Figure 2. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2021-2032) & (US$ Million) Figure 4. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales (2021-2032) & (K Units) Figure 5. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 T-Cell & NK-Cell Engaging Bispecific Antibodies Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. T-Cell Engagers Image Figure 9. NK-Cell Engagers Image Figure 10. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2021-2032) Figure 13. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Type (2021-2032) Figure 16. Hematological Cancers Image Figure 17. Solid Tumors Image Figure 18. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2021-2032) Figure 21. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Application (2021-2032) Figure 24. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country (2021-2032) Figure 26. U.S. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country (2021-2032) Figure 31. Germany T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country (2021-2032) Figure 38. China T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Country (2021-2032) Figure 46. Brazil T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile T-Cell & NK-Cell Engaging Bispecific Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (2021-2032) & (US$ Million) Figure 57. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (2021-2032) & (US$ Million) Figure 59. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. T-Cell & NK-Cell Engaging Bispecific Antibodies Value Chain Figure 65. Manufacturing Cost Structure Figure 66. T-Cell & NK-Cell Engaging Bispecific Antibodies Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • T-Cell Engagers
  • NK-Cell Engagers
Applications
  • Hematological Cancers
  • Solid Tumors
Companies covered
  • Immunocore
  • MacroGenics
  • Regeneron
  • AbbVie
  • Amgen
  • Pfizer
  • Roche
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Dynamics
  1. 2.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Trends
  2. 2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Drivers
  3. 2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Opportunities and Challenges
  4. 2.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Restraints
3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market by Manufacturers
  1. 3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Manufacturers (2021-2026)
  2. 3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Manufacturers (2021-2026)
  3. 3.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturers, Product Type & Application
  7. 3.7 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 T-Cell & NK-Cell Engaging Bispecific Antibodies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 T-Cell & NK-Cell Engaging Bispecific Antibodies Tier 1, Tier 2, and Tier 3
4 T-Cell & NK-Cell Engaging Bispecific Antibodies Market by Type
  1. 4.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Type Introduction
  2. 4.1.1 T-Cell Engagers
  3. 4.1.2 NK-Cell Engagers
  4. 4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type
  5. 4.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Type (2021-2032)
  7. 4.2.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2021-2032)
  8. 4.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type
  9. 4.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Type (2021-2032)
  11. 4.3.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Type (2021-2032)
5 T-Cell & NK-Cell Engaging Bispecific Antibodies Market by Application
  1. 5.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Application Introduction
  2. 5.1.1 Hematological Cancers
  3. 5.1.2 Solid Tumors
  4. 5.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application
  5. 5.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Application (2021-2032)
  7. 5.2.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2021-2032)
  8. 5.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application
  9. 5.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Application (2021-2032)
  11. 5.3.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Application (2021-2032)
6 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region
  1. 6.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2021-2032)
  3. 6.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region (2021-2026)
  4. 6.2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region
  1. 7.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region
  2. 7.1.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region (2021-2026)
  4. 7.1.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region (2027-2032)
  5. 7.1.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (2021-2032)
  8. 7.2.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (2021-2032)
  11. 7.3.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Immunocore
  2. 8.1.1 Immunocore Company Information
  3. 8.1.2 Immunocore Business Overview
  4. 8.1.3 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  6. 8.1.5 Immunocore Recent Developments
  7. 8.2 MacroGenics
  8. 8.2.1 MacroGenics Company Information
  9. 8.2.2 MacroGenics Business Overview
  10. 8.2.3 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  12. 8.2.5 MacroGenics Recent Developments
  13. 8.3 Regeneron
  14. 8.3.1 Regeneron Company Information
  15. 8.3.2 Regeneron Business Overview
  16. 8.3.3 Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  18. 8.3.5 Regeneron Recent Developments
  19. 8.4 AbbVie
  20. 8.4.1 AbbVie Company Information
  21. 8.4.2 AbbVie Business Overview
  22. 8.4.3 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  24. 8.4.5 AbbVie Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Johnson & Johnson
  44. 8.8.1 Johnson & Johnson Company Information
  45. 8.8.2 Johnson & Johnson Business Overview
  46. 8.8.3 Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Product Portfolio
  48. 8.8.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Value Chain Analysis
  2. 9.1.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Production Mode & Process
  6. 9.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Distributors
  9. 9.2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst